SteelPeak Wealth LLC Has $745,000 Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY

SteelPeak Wealth LLC reduced its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 45.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,635 shares of the biopharmaceutical company’s stock after selling 1,373 shares during the period. SteelPeak Wealth LLC’s holdings in Alnylam Pharmaceuticals were worth $745,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Generali Asset Management SPA SGR lifted its position in Alnylam Pharmaceuticals by 6,368.0% during the 3rd quarter. Generali Asset Management SPA SGR now owns 3,234 shares of the biopharmaceutical company’s stock worth $1,475,000 after acquiring an additional 3,184 shares during the last quarter. True Wealth Design LLC increased its stake in shares of Alnylam Pharmaceuticals by 1,528.6% in the third quarter. True Wealth Design LLC now owns 228 shares of the biopharmaceutical company’s stock worth $104,000 after purchasing an additional 214 shares during the period. Salomon & Ludwin LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth about $27,000. Merit Financial Group LLC lifted its position in shares of Alnylam Pharmaceuticals by 123.9% during the 3rd quarter. Merit Financial Group LLC now owns 4,231 shares of the biopharmaceutical company’s stock worth $1,930,000 after purchasing an additional 2,341 shares during the last quarter. Finally, Meridian Financial Advisors LLC boosted its stake in Alnylam Pharmaceuticals by 3.5% during the 3rd quarter. Meridian Financial Advisors LLC now owns 828 shares of the biopharmaceutical company’s stock valued at $378,000 after purchasing an additional 28 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Kevin Joseph Fitzgerald sold 12,128 shares of the stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $452.18, for a total value of $5,484,039.04. Following the completion of the transaction, the executive vice president directly owned 21,264 shares of the company’s stock, valued at approximately $9,615,155.52. This represents a 36.32% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Yvonne Greenstreet sold 15,650 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $453.69, for a total value of $7,100,248.50. Following the transaction, the chief executive officer owned 65,409 shares of the company’s stock, valued at $29,675,409.21. This trade represents a 19.31% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 37,778 shares of company stock valued at $17,096,988 in the last three months. Company insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Trading Up 0.6%

Shares of ALNY stock opened at $400.17 on Friday. The firm has a fifty day moving average of $432.07 and a 200-day moving average of $417.39. The stock has a market cap of $52.87 billion, a price-to-earnings ratio of 1,667.38 and a beta of 0.32. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $495.55. The company has a debt-to-equity ratio of 4.45, a quick ratio of 2.49 and a current ratio of 2.54.

Wall Street Analyst Weigh In

ALNY has been the topic of several recent analyst reports. Royal Bank Of Canada lifted their price target on Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the stock an “outperform” rating in a research report on Friday, September 19th. Wall Street Zen upgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Monday, November 10th. Oppenheimer reiterated an “outperform” rating and set a $500.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, October 31st. JPMorgan Chase & Co. decreased their price target on shares of Alnylam Pharmaceuticals from $475.00 to $473.00 and set an “overweight” rating on the stock in a research report on Monday, October 13th. Finally, Morgan Stanley boosted their price objective on shares of Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the stock an “equal weight” rating in a report on Monday, October 6th. Twenty-three equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $477.44.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.